Mednet Logo

How would you manage a patient with MSS, KRAS mutated locally advanced rectal adenocarcinoma with a mixed response to neoadjuvant FOLFOX?

This involves the primary site responding but progression with new bone marrow involvement with resulting cytopenias.
1 Answer
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University of Wisconsin
Answered on

If there is new bone marrow involvement, I assume you confirmed this with a bone marrow biopsy? This would be a very unusual location for rectal cancer, so to speak. If you have not done a BMB, I would obtain pathologic proof of bone involvement. That would make this patient stage IV, in which case,...

Join for free or sign in to see the full answer